Bill Martin, globalhead of neuroscience for R&D, Janssen

J&J’s neu­ro­science re­nais­sance? Janssen R&D chief ready­ing for 'gold­en age'

J&J’s Janssen neu­ro­science di­vi­sion has been a sol­id rev­enue con­trib­u­tor fo­cused most­ly on psy­chi­atric drugs — but now its port­fo­lio is head­ed for a change.

Bill Mar­tin, Janssen’s glob­al head of neu­ro­science for re­search and de­vel­op­ment now for 18 months, is look­ing to build out pre­ci­sion prod­ucts as neu­ro­science “en­ters a gold­en age.”

The phar­ma is now “ex­pand­ing our com­mer­cial port­fo­lio be­yond psy­chi­a­try and in­tro­duc­ing new ther­a­pies across neu­ro­log­i­cal neu­rode­gen­er­a­tive and au­toan­ti­body dri­ven dis­eases,” he said in an in­ter­view with End­points Mar­ket­ingRx.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.